Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will
be tested for the treatment of women with endometriosis recurrence compared with classical
GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will
be the outcomes for establishing which medical treatment is the best in endometriosis
recurrence treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Centre for Endocrinology and Reproductive Medicine, Italy